Advertisement
Featured new investigator| Volume 153, ISSUE 1, P11-16, January 2009

Download started.

Ok

Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients

Published:December 08, 2008DOI:https://doi.org/10.1016/j.trsl.2008.11.002
      Our specific aims were to determine whether low serum 25 (OH) vitamin D (D2 + D3) (<32 ng/mL) was associated with myalgia in statin-treated patients and whether the myalgia could be reversed by vitamin D supplementation while continuing statins. After excluding subjects who took corticosteroids or supplemental vitamin D, serum 25 (OH) D was measured in 621 statin-treated patients, which consisted of 128 patients with myalgia at entry and 493 asymptomatic patients. The 128 myalgic patients had lower mean ± standard deviation (SD) serum vitamin D than the 493 asymptomatic patients (28.6 ± 13.2 vs 34.2 ± 13.8 ng/mL, P < 0.0001), but they did not differ (p > 0.05) by age, body mass index (BMI), type 2 diabetes, or creatine kinase levels. By analysis of variance, which was adjusted for race, sex, and age, the least square mean (± standard error [SE]) serum vitamin D was lower in the 128 patients with myalgia than in the 493 asymptomatic patients (28.7 ± 1.2 vs 34.3 ± 0.6 ng/mL, P < 0.0001). Serum 25 (OH) D was low in 82 of 128 (64%) patients with myalgia versus 214 of 493 (43%) asymptomatic patients (χ2 = 17.4, P < 0.0001). Of the 82 vitamin-D–deficient, myalgic patients, while continuing statins, 38 were given vitamin D (50,000 units/week for 12 weeks), with a resultant increase in serum vitamin D from 20.4 ± 7.3 to 48.2 ± 17.9 ng/mL (P < 0.0001) and resolution of myalgia in 35 (92%). We speculate that symptomatic myalgia in statin-treated patients with concurrent vitamin D deficiency may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle.

      Abbreviations:

      BMI (body mass index), CK (creatine kinase)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Holick M.F.
        • Chen T.C.
        Vitamin D deficiency: a worldwide problem with health consequences.
        Am J Clin Nutr. 2008; 87: 1080S-1086S
        • Mark S.
        • Gray-Donald K.
        • Delvin E.E.
        • et al.
        Low vitamin D status in a representative sample of youth from Quebec, Canada.
        Clin Chem. 2008; 54: 1283-1289
        • Goswami R.
        • Mishra S.K.
        • Kochupillai N.
        Prevalence & potential significance of vitamin D deficiency in Asian Indians.
        Indian J Med Res. 2008; 127: 229-238
        • Alsafwah S.
        • Laguardia S.P.
        • Nelson M.D.
        • et al.
        Hypovitaminosis D in African Americans residing in Memphis, Tennessee with and without heart failure.
        Am J Med Sci. 2008; 335: 292-297
        • Erkal M.Z.
        • Wilde J.
        • Bilgin Y.
        • et al.
        High prevalence of vitamin D deficiency, secondary hyperparathyroidism and generalized bone pain in Turkish immigrants in Germany: identification of risk factors.
        Osteoporos Int. 2006; 17: 1133-1140
        • Bischoff-Ferrari H.A.
        • Dietrich T.
        • Orav E.J.
        • et al.
        Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y.
        Am J Clin Nutr. 2004; 80: 752-758
        • Lips P.
        Vitamin D physiology.
        Prog Biophys Mol Biol. 2006; 92: 4-8
        • Targher G.
        • Bertolini L.
        • Padovani R.
        • et al.
        Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients.
        Clin Endocrinol (Oxf). 2006; 65: 593-597
        • Nichols G.A.
        • Koro C.E.
        Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.
        Clin Ther. 2007; 29: 1761-1770
        • McClure D.L.
        • Valuck R.J.
        • Glanz M.
        • Murphy J.R.
        • Hokanson J.E.
        Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.
        J Clin Epidemiol. 2007; 60: 812-818
        • Tsugawa N.
        • Suhara Y.
        • Kamao M.
        • Okano T.
        Determination of 25-hydroxyvitamin D in human plasma using high-performance liquid chromatography—tandem mass spectrometry.
        Anal Chem. 2005; 77: 3001-3007
        • Ford E.S.
        • Ajani U.A.
        • McGuire L.C.
        • Liu S.
        Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults.
        Diabetes Care. 2005; 28: 1228-1230
        • Bischoff-Ferrari H.A.
        • Giovannucci E.
        • Willett W.C.
        • Dietrich T.
        • Dawson-Hughes B.
        Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes.
        Am J Clin Nutr. 2006; 84: 18-28
        • Thompson P.D.
        • Clarkson P.
        • Karas R.H.
        Statin-associated myopathy.
        JAMA. 2003; 289: 1681-1690
        • Ybarra J.
        • Sanchez-Hernandez J.
        • Perez A.
        Hypovitaminosis D and morbid obesity.
        Nurs Clin North Am. 2007; 42 (v): 19-27
        • Sentongo T.A.
        • Semaeo E.J.
        • Stettler N.
        • Piccoli D.A.
        • Stallings V.A.
        • Zemel B.S.
        Vitamin D status in children, adolescents, and young adults with Crohn disease.
        Am J Clin Nutr. 2002; 76: 1077-1081
        • Link E.
        • Parish S.
        • Armitage J.
        • et al.
        SLCO1B1 variants and statin-induced myopathy–a genomewide study.
        N Engl J Med. 2008; 359: 789-799
        • Fuleihan G.E.
        • Deeb M.
        Hypovitaminosis D in a sunny country.
        N Engl J Med. 1999; 340: 1840-1841
        • Nesby-O'Dell S.
        • Scanlon K.S.
        • Cogswell M.E.
        • et al.
        Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994.
        Am J Clin Nutr. 2002; 76: 187-192
        • Hannan M.T.
        • Litman H.J.
        • Araujo A.B.
        • et al.
        Serum 25-hydroxyvitamin D and bone mineral density in a racially and ethnically diverse group of men.
        J Clin Endocrinol Metab. 2008; 93: 40-46
        • Zittermann A.
        Vitamin D in preventive medicine: are we ignoring the evidence?.
        Br J Nutr. 2003; 89: 552-572
        • Pfeifer M.
        • Begerow B.
        • Minne H.W.
        Vitamin D and muscle function.
        Osteoporos Int. 2002; 13: 187-194
        • Shinchuk L.M.
        • Holick M.F.
        Vitamin d and rehabilitation: improving functional outcomes.
        Nutr Clin Pract. 2007; 22: 297-304
        • Ziambaras K.
        • Dagogo-Jack S.
        Reversible muscle weakness in patients with vitamin D deficiency.
        West J Med. 1997; 167: 435-439
        • Goldstein M.R.
        Myopathy, statins, and vitamin D deficiency.
        Am J Cardiol. 2007; 100: 1328
        • Bunout D.
        • Barrera G.
        • Leiva L.
        • et al.
        Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects.
        Exp Gerontol. 2006; 41: 746-752
        • Glueck C.J.
        • Aregawi D.
        • Agloria M.
        • et al.
        Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
        Clin Ther. 2006; 28: 933-942